{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:11:18Z","timestamp":1789186278256,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100022849","name":"Universidade Positivo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100022849","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Human papillomavirus (HPV) infection is highly prevalent worldwide and is associated with a broad spectrum of anogenital diseases, including vulvar condylomas and malignancies. Immunosuppression plays a key role in HPV persistence, recurrence, and progression; however, data on the clinical course of vulvar condylomas in immunocompromised women remain limited. This retrospective cohort study evaluated clinical progression, treatment response, recurrence, and neoplastic outcomes in women diagnosed with vulvar condyloma between January 2008 and January 2021 at a tertiary referral center in Brazil. Immunosuppressed patients, including women living with HIV, those receiving immunosuppressive therapy for autoimmune diseases, and patients undergoing chemotherapy, were compared with an age-matched immunocompetent group. Among 294 women included, 41 (13.9%) were immunosuppressed. Lesion extent was significantly greater in immunosuppressed patients, although lesion number did not differ between groups. Clinical remission after first-line treatment was significantly lower among immunosuppressed women (21.9%vs55.0%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001; OR\u2009=\u20094.5) with a higher need for multiple treatment sessions. Similarly, the complete remission rate at the end of follow-up was higher for the immunocompetent patients (75.9% vs. 48.8%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001; OR\u2009=\u20093.3). Immunosuppressed women had a 2.3-fold increased risk of recurrence and a higher risk of progression to vulvar intraepithelial neoplasia (OR\u2009=\u20096.7) and invasive disease (OR\u2009=\u20098.5). In the HIV patients, recurrence was not associated with CD4T-lymphocyte count or HIV viral load. These findings indicate that immunosuppressed women with vulvar condylomas experience more extensive disease, poorer treatment response, higher recurrence rates, and an increased risk of neoplastic progression, highlighting the importance of closer surveillance and individualized management in this high-risk population.\n                  <\/jats:p>","DOI":"10.1007\/s12026-026-09843-6","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:56:57Z","timestamp":1789185417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Course and Treatment Outcomes of Vulvar Condylomas in Immunocompromised Women: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0162-9893","authenticated-orcid":false,"given":"Fernanda Villar","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9549-2035","authenticated-orcid":false,"given":"Camilly Eduarda","family":"Kmita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0200-9802","authenticated-orcid":false,"given":"Carlos Afonso","family":"Maestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6196-0812","authenticated-orcid":false,"given":"Isabela Ceschin","family":"Maestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1234-8093","authenticated-orcid":false,"given":"Renato","family":"Nisihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"issue":"10","key":"9843_CR1","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3390\/pathogens14101043","volume":"14","author":"N West","year":"2025","unstructured":"West N, Boz V, Zanotta N, Cason C, Campisciano G, Casuccio A, et al. Hum Papillomavirus: Old New History Pathogens. 2025;14(10):1043. https:\/\/doi.org\/10.3390\/pathogens14101043.","journal-title":"Hum Papillomavirus: Old New History Pathogens"},{"issue":"2","key":"9843_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/LGT.0000000000000866","volume":"29","author":"A-B Moscicki","year":"2025","unstructured":"Moscicki A-B, Flowers L, Huchko MJ, et al. Updated Review for Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. J Low Genit Tract Dis. 2025;29(2):168\u201379.","journal-title":"J Low Genit Tract Dis"},{"issue":"1","key":"9843_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/COH.0000000000000991","volume":"21","author":"RK Scott","year":"2026","unstructured":"Scott RK, Powell AM, Jao J. Contemporary issues in gynecologic and reproductive health for women with HIV. Curr Opin HIV AIDS. 2026;21(1):40\u20135. https:\/\/doi.org\/10.1097\/COH.0000000000000991.","journal-title":"Curr Opin HIV AIDS"},{"issue":"9","key":"9843_CR4","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/life15091365","volume":"15","author":"M Terrinoni","year":"2025","unstructured":"Terrinoni M, Golia D\u2019Aug\u00e8 T, D\u2019Oria O, Palisciano M, Adinolfi F, Rossetti D, et al. Viral Infections of the Vulva: A Narrative Review. Life (Basel). 2025;15(9):1365. https:\/\/doi.org\/10.3390\/life15091365.","journal-title":"Life (Basel)"},{"issue":"16","key":"9843_CR5","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1016\/j.ejca.2013.06.033","volume":"49","author":"S de Sanjos\u00e9","year":"2013","unstructured":"de Sanjos\u00e9 S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, et al. HPV VVAP study group. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49(16):3450\u201361. https:\/\/doi.org\/10.1016\/j.ejca.2013.06.033.","journal-title":"Eur J Cancer"},{"key":"9843_CR6","doi-asserted-by":"publisher","first-page":"927131","DOI":"10.3389\/fcimb.2022.927131","volume":"12","author":"L Ntuli","year":"2022","unstructured":"Ntuli L, Mtshali A, Mzobe G, Liebenberg LJ, Ngcapu S. Role of Immunity and Vaginal Microbiome in Clearance and Persistence of Human Papillomavirus Infection. Front Cell Infect Microbiol. 2022;12:927131. https:\/\/doi.org\/10.3389\/fcimb.2022.927131.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"9843_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/v17040498","volume":"17","author":"G Catalano","year":"2025","unstructured":"Catalano G, Clemente T, Diotallevi S, Lolatto R, Trentacapilli B, Ranzenigo M, et al. Prevalence of Sexually Transmitted Infections Among Cisgender Women Coming to a Walk-In Center. Viruses. 2025;17(4):498. https:\/\/doi.org\/10.3390\/v17040498.","journal-title":"Viruses"},{"issue":"1","key":"9843_CR8","doi-asserted-by":"publisher","first-page":"e14355","DOI":"10.1111\/dth.14355","volume":"34","author":"V Hammerl","year":"2021","unstructured":"Hammerl V, Parlar B, Navarini A, Gantenbein L, V\u00e4th H, Mueller SM. Mucosal side effects in patients treated with topical imiquimod-A scoping review of the literature. Dermatol Ther. 2021;34(1):e14355. https:\/\/doi.org\/10.1111\/dth.14355.","journal-title":"Dermatol Ther"},{"issue":"1","key":"9843_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12967-021-02845-y","volume":"19","author":"X Lyu","year":"2021","unstructured":"Lyu X, Li G, Qiao Q. Identification of an immune classification for cervical cancer and integrative analysis of multiomics data. J Transl Med. 2021;19(1):200. https:\/\/doi.org\/10.1186\/s12967-021-02845-y.","journal-title":"J Transl Med"},{"key":"9843_CR10","doi-asserted-by":"publisher","first-page":"1591297","DOI":"10.3389\/fimmu.2025.1591297","volume":"16","author":"EW Kiamba","year":"2025","unstructured":"Kiamba EW, Goodier MR, Clarke E. Immune responses to human papillomavirus infection and vaccination. Front Immunol. 2025;16:1591297. https:\/\/doi.org\/10.3389\/fimmu.2025.1591297.","journal-title":"Front Immunol"},{"issue":"5","key":"9843_CR11","doi-asserted-by":"publisher","first-page":"112508","DOI":"10.1016\/j.celrep.2023.112508","volume":"42","author":"S Miyauchi","year":"2023","unstructured":"Miyauchi S, Kim SS, Jones RN, Zhang L, Guram K, Sharma S, et al. Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway. Cell Rep. 2023;42(5):112508. https:\/\/doi.org\/10.1016\/j.celrep.2023.112508.","journal-title":"Cell Rep"},{"key":"9843_CR12","doi-asserted-by":"publisher","first-page":"1645019","DOI":"10.3389\/fimmu.2025.1645019","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Deng J, Liu Y, Yu S. HPV infection and the immune microenvironment in cervical cancer. Front Immunol. 2025;16:1645019. https:\/\/doi.org\/10.3389\/fimmu.2025.1645019.","journal-title":"Front Immunol"},{"issue":"5","key":"9843_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/GCO.0000000000001054","volume":"37","author":"C Haigh","year":"2025","unstructured":"Haigh C, Sun HY, Fischer G. Diagnosis and management of vulval lesions. Curr Opin Obstet Gynecol. 2025;37(5):317\u201325. https:\/\/doi.org\/10.1097\/GCO.0000000000001054.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"5","key":"9843_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/09564624241311629","volume":"36","author":"SK Edwards","year":"2025","unstructured":"Edwards SK, Lewis F, Fernando I, Haddon L, Grover D. 2024 British Association for Sexual Health and HIV (BASHH) UK national guideline on the management of vulval conditions. Int J STD AIDS. 2025;36(5):346\u201371. https:\/\/doi.org\/10.1177\/09564624241311629.","journal-title":"Int J STD AIDS"},{"key":"9843_CR15","unstructured":"CDC. 2021. Anogenital warts. Sexually transmitted infections treatment guidelines, 2021. https:\/\/www.cdc.gov\/std\/treatment-guidelines\/anogenital-warts.htm. Acess: 18 Aug 2026."},{"issue":"7","key":"9843_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s11912-025-01675-1","volume":"27","author":"N - Gallio","year":"2025","unstructured":"Gallio N, Preti M, Casetta E, Albuquerque A, Vieira-Baptista P, Borella F, et al. Imiquimod for Anal High Grade Intraepithelial Neoplasia: A Systematic Review. Curr Oncol Rep. 2025;27(7):833\u201343. https:\/\/doi.org\/10.1007\/s11912-025-01675-1.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"9843_CR17","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.31557\/APJCP.2025.26.10.3549","volume":"26","author":"ADV Graca","year":"2025","unstructured":"Graca ADV, Soares LC, Brollo JLA. Barriers to HPV Vaccination in Brazil: A Systematic Review. Asian Pac J Cancer Prev. 2025;26(10):3549\u201360. https:\/\/doi.org\/10.31557\/APJCP.2025.26.10.3549.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"spe1","key":"9843_CR18","doi-asserted-by":"publisher","first-page":"e2020790","DOI":"10.1590\/S1679-4974202100014.esp1","volume":"30","author":"NS Carvalho","year":"2021","unstructured":"Carvalho NS, Silva RJCD, Val ICD, Bazzo ML, Silveira MFD. [Brazilian Protocol for Sexually Transmitted Infections 2020: human papillomavirus (HPV) infection. Epidemiol Serv Saude. 2021;30(spe1):e2020790. https:\/\/doi.org\/10.1590\/S1679-4974202100014.esp1.","journal-title":"Epidemiol Serv Saude"},{"key":"9843_CR19","unstructured":"Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Nonavalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. July 17. 2024. Available at https:\/\/www.cdc.gov\/acip-recs\/hcp\/vaccine-specific\/hpv.html"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09843-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09843-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09843-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:57:04Z","timestamp":1789185424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09843-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9843"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09843-6","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Committee of Ethics in Research from Institution under protocol number 6.566.826.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Statement: During the preparation of this work the authors used ChatGPT with the aim of correcting spelling and grammar in the English language. After using this tool\/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":3,"name":"Ethics","label":"<b>Declaration of generative AI and AI-assisted technologies in the manuscript preparation process<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"109"}}